Pfizer’s experimental oral drug to treat Covid-19 at the first sign of illness could be available by the end of the year
Key Points:
- Pill can cure the disease at the first sign.
- Inhibits the enzyme, virus needs to multiply in the human cell
- These inhibitors were used to treat HIV, hepatitis C
Pfizer has come with good news for the whole world. In his recent video interview with CNBC, CEO Albert Bourla said that the pills, which are said to cure the coronavirus in a single pill, will be available by the end of this year. This pill is said to treat corona and cure it at the first sign,
Pfizer has been experimenting with this oral treatment drug since the first report of the Covid-19. They have started the human trials and are getting positive and optimistic results. Albert said that after their vaccine success, this pill would also be a great success. This is to be noted that Pfizer’s vaccine has 90% efficacy and helped the States to get back to their normal lives.
“It has been a horrible situation in India and other places of the world, and availability of vaccines has been low. The way I see it, it is a big issue and needs to be addressed. It is not only ethically unacceptable, but in a pandemic, you are as protected as your neighbor. If we do not provide the solutions for them, they will become the pool where the virus will replicate.” Albert said in an interview with CNBC in the show, Inspiring America. Suppose clinical preliminaries work out positively and the Food and Medication Organization supports it. In that case, the medication could be conveyed across the U.S. before the year’s over, Bourla told CNBC’s “Squawk Box.”
Wellbeing specialists say the medication, taken by mouth, could be a distinct advantage since individuals recently contaminated with the infection could utilize it outside of clinics. In addition, scientists trust the drug will hold the disease back from advancing and forestall medical clinic trips.
In a statement, Pfizer said that the Phase-1 trial is going on in the USA. The oral antiviral protease inhibitor has shown some excellent response in suppressing the enzymes, which allows the virus to multiply.
This trial is a randomized, double-blind, sponsor-open. If everything goes right, phase 2 and phase 3 trials will increase the number of people, and by the end of the year, we can get the oral treatment.